Need of stratifying patients according to severity of underlying liver disease for hepatocellular carcinoma patients undergoing systemic therapy trials.
Yeo
W
W
Mo
F K F
FK
Hui
P
P
Chan
S L
SL
D000970:Antineoplastic Agents / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D008107:Liver Diseases / Q000503:physiopathology*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D011379:Prognosis; D020379:Risk Adjustment; D012720:Severity of Illness Index; D016019:Survival Analysis
D000970:Antineoplastic Agents